ALVAL.PA rises 15.79% to €1.10 on 30 Jan 2026 (EURONEXT): watch volume
ALVAL.PA stock led some of today’s top gainers on EURONEXT, rising 15.79% to €1.10 on 30 Jan 2026 as volume spiked to 2,680,090 shares. The move follows a run above the 50-day average price of €0.71 and a push toward the year high of €1.46. Traders priced in pipeline progress and short-covering into the close, making ALVAL.PA one of the most active biotech tickers in Europe today.
ALVAL.PA stock: Price action and volume
Intraday action showed a low of €0.87 and a high of €1.10, with the stock opening at €0.91 and closing at €1.10. Volume was 2,680,090 versus an average volume of 437,549, a relative volume of 2.33 that signals above-normal trading interest.
One clear driver of the move was momentum into short-term averages: the 50-day average is €0.71 and the 200-day average is €0.83, so today’s close sits materially above the 50-day but near the 200-day.
Valuation and fundamentals for ALVAL.PA stock
Valbiotis SA (ALVAL.PA) shows a market cap of €24,840,207.00 and negative earnings metrics with EPS -0.70 and PE -1.50, reflecting ongoing R&D spend. Price-to-book sits near 1.60, while price-to-sales is elevated at 52.63, driven by low revenues per share of €0.03.
The company holds €0.73 cash per share and a current ratio of 3.04, indicating liquidity buffer despite negative operating cash flow per share of -€0.61.
Clinical pipeline and catalysts affecting ALVAL.PA stock
Valbiotis is a France-based biotech developing TOTUM-series compounds for metabolic and cardiovascular indications, including TOTUM-63 in Phase II/III for type 2 diabetes and TOTUM-854 in Phase II/III for hypertension. Strategic tie-ups such as the Nestlé Health Science partnership remain key catalysts.
Upcoming corporate dates include an earnings announcement on 02 Mar 2026, and any positive trial readouts or regulatory updates would likely drive additional upside and liquidity for ALVAL.PA.
Technicals and trading setup for ALVAL.PA stock
Momentum indicators are mixed: RSI at 50.24 and ADX at 17.41 suggest no strong trend yet. Bollinger Bands range is €0.64–€0.73 and ATR is €0.04, highlighting modest intraday volatility relative to price.
The stock’s on‑balance volume sits at 1,360,878, and short-term momentum readings point to potential continuation if volume remains above the 50‑day average.
Meyka AI grade and forecast for ALVAL.PA stock
Meyka AI rates ALVAL.PA with a score of 58.32 out of 100 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a quarterly price of €0.83 and a monthly price of €0.47. Compared with the current price of €1.10, the model implies a near-term downside to the quarterly projection of -24.55%. Forecasts are model-based projections and not guarantees.
Risks, sector context and trading ideas
ALVAL.PA sits in Healthcare/Biotechnology in Europe where the sector YTD performance is slightly negative; biotech names remain sensitive to trial outcomes and news flow. Key risks include continued negative earnings (EPS -0.70), high price-to-sales, and cash burn driving dilution.
Traders seeking exposure can consider event-driven strategies around the March earnings date or use tight risk controls given the stock’s high intraday volume and limited free-float liquidity.
Final Thoughts
Today’s 15.79% gain to €1.10 made ALVAL.PA one of the top gainers on EURONEXT as traders reacted to heavy volume and pipeline speculation. Fundamentals show cash per share €0.73, EPS -0.70, and elevated price-to-sales 52.63, so valuation remains stretched without positive clinical milestones. Meyka AI’s forecast model projects a quarterly price of €0.83, implying -24.55% from today’s close; this underlines the market’s binary risk-reward for biotech development plays. Scenario targets: bull €1.50, base €1.20, bear €0.80—use stop-losses and position-sizing if you trade around trial catalysts. For more company details see the official site and company updates: Valbiotis and the company LinkedIn page Valbiotis LinkedIn. Meyka AI provided the above as an AI-powered market analysis platform; forecasts and grades are not investment advice and are model projections, not guarantees.
FAQs
What caused ALVAL.PA stock to surge today?
The rise to €1.10 and 15.79% gain was driven by heavy trading volume (2,680,090), movement above the 50-day average, and investor focus on Valbiotis’ clinical pipeline and upcoming earnings on 02 Mar 2026.
What is Meyka AI’s rating for ALVAL.PA stock?
Meyka AI rates ALVAL.PA 58.32/100 (Grade C+, Suggestion: HOLD). This score combines benchmark, sector, financial growth, metrics, forecasts, and analyst consensus; it is informational, not financial advice.
What price targets and forecast does Meyka AI give for ALVAL.PA stock?
Meyka AI’s forecast model projects a quarterly price of €0.83 and a monthly price of €0.47. Scenario targets: bull €1.50, base €1.20, bear €0.80. Forecasts are model-based and not guarantees.
What are the main risks for ALVAL.PA stock?
Primary risks include negative EPS (-0.70), high price-to-sales (52.63), potential dilution from financing, and binary clinical outcomes. Liquidity can amplify moves around news events.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
